Interesting data from #STERIMGLI at #EANO2026 on #re-irradiation + #durvalumab for recurrent glioblastoma:

➡️ HF-SRT 24 Gy/3 fx
➡️ Primary OS endpoint not met in ITT population (16.1 vs 13.3 months)
➡️ QoL and cognition maintained
➡️ Exploratory analyses suggest a stronger OS in WHO 2021 glioblastoma

Durvalumab Plus FLOT Boosts Survival in Resectable Gastric and GEJ Cancer, MATTERHORN Shows

#oncology #immunotherapy #durvalumab #gastric-cancer #astrazeneca

🚨Phase 3 DeLLphi-305 showed that #tarlatamab-dlle (#IMDELLTRA, Amgen) + #durvalumab (#IMFINZI, AstraZeneca) significantly improved overall survival versus durvalumab alone in the first-line maintenance setting.